Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2571 - Supportive care: patient expectations, availability and uptake

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Helene Simon

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

H. Simon1, J. Viguier2, G.M. Ganem3, C. Touboul4, C. Lhomel5, H. Naman6, J.F. Morère7, F. Eisinger8

Author affiliations

  • 1 Medical Oncoloy, CHRU Brest Hôpital Morvan, 29200 - Brest/FR
  • 2 Medical Oncology, CHRU Bretonneau, 37044 - Tours/FR
  • 3 Medical Oncology, Clinique Victor Hugo, 72015 - Le Mans/FR
  • 4 Statistics, Kantar Health, 75014 - Paris/FR
  • 5 Medical, Roche, 9265000 - Boulogne-Billancourt/FR
  • 6 Oncology, Centre Azuréen Cancérologie, 06250 - Mougins/FR
  • 7 Oncology, Hôpital Paul Brousse, 94800 - Villejuif/FR
  • 8 Département D'anticipation Et De Suivi Du Cancer Dasc, Institute Paoli Calmettes, 13274 - Marseille/FR
More

Resources

Abstract 2571

Background

Integrative oncology uses complementary approaches alongside conventional medical therapy to improve quality of life, improve outcomes and reduce the risk of recurrence. The Calista2 survey sought to identify, understand, and rank cancer patients’ expectations and utilization of supportive care and activities. Accessibility of such supportive care was also assessed.

Methods

The 82 physicians who accepted to take part in the survey recruited 666 patients. Inclusion criteria were: patients already on specific therapy for breast cancer (BC), colorectal cancer (CC) or lung cancer (LC). Patient questionnaires were self-reported. Questions covered drug management of pain, fatigue, adverse effects of treatments (AE), and sleep disorders, social and psychological support, physical activities, and complementary and alternative medicines. Questionnaires were collected between September 2016 and October 2017. This analysis focuses on the patients' expectations, the supportive care or activity made available to patients, and how they were used.

Results

After exclusion of non-valid patient questionnaires, 467 were analyzed. All cancer localizations combined, patients rated the medical management of adverse events (AE) and pain as highly important (>7/10). Of the 18 items considered, physical activity and management of fatigue were rated as moderately important (5-7/10). The different types of supportive care or activity provided included predominantly the management of adverse events (AE, 81%) and pain (72%), psychological support (56%), and diet/nutrition (49%). Patients primarily used drug management of AE (72%) and pain (61%), diet/nutrition (34%), and self-image improvement techniques (31%). There is a lack of availability of complementary medicine, fatigue management, and relaxation techniques according to 28%, 27% and 24% of patients, respectively.

Conclusions

In our sample, the complementary approaches currently available practically satisfied patient requirements with regards to management of AE and pain. However, these findings also highlight the need for greater access to fatigue management, complementary medicine, and relaxation techniques.

Clinical trial identification

Legal entity responsible for the study

Kantar Health.

Funding

Roche.

Editorial Acknowledgement

Medical writing assistance was provided by Potentiel d’Action (France).

Disclosure

H. Simon, G.M. Ganem, H. Naman, J.F. Morère, F. Eisinger: Honorarium: Roche. C. Lhomel: Employee: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.